Aaron S Kesselheim1, Sarah A McGraw2, Sara Z Dejene3, Paula Rausch4, Gerald J Dal Pan4, Brian M Lappin4, Esther H Zhou4, Jerry Avorn3, Eric G Campbell5. 1. Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St., Suite 3030, Boston, MA, 02120, USA. akesselheim@partners.org. 2. The Hastings Center, Garrison, NY, USA. 3. Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St., Suite 3030, Boston, MA, 02120, USA. 4. US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, USA. 5. Mongan Institute Health Policy Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Abstract
INTRODUCTION: The US Food and Drug Administration uses drug safety communications (DSCs) to release emerging information regarding post-market safety issues, but it is unclear the extent of awareness by patients and providers of these communications and their specific recommendations. OBJECTIVE: We conducted semi-structured interviews with patients and physicians to evaluate their awareness and understanding of emerging drug safety information related to two sleep aids: zolpidem or eszopiclone. METHODS: We conducted interviews with 40 patients and ten physicians recruited from a combination of insurer claims databases and online sources. We evaluated (1) sources of drug safety information; (2) discussions between patients and physicians about the two medications; (3) their knowledge of the DSC; and (4) preferences for learning about future drug safety information. Interviews were transcribed and analyzed thematically. RESULTS: Patients cited their physicians, pharmacy inserts, and the Internet as sources of drug safety information. Physicians often referred to medical journals and online medical sources. Most patients reported being aware of information contained in the DSC summaries they were read. Almost all patients and physicians reported discussing side effects during patient-provider conversations, but almost no patients mentioned that physicians had communicated with them key messaging from the DSCs at issue: the risk of next-morning impairment with zolpidem and the lower recommended initial dose for women. CONCLUSIONS: Some risks of medications are effectively communicated to patients and physicians; however, there is still a noticeable gap between information issued by the Food and Drug Administration and patient and physician awareness of this knowledge, as well as patients' decisions to act on this information. Disseminators of emerging drug safety information should explore ways of providing user-friendly resources to patients and healthcare professionals that can update them on new risks in a timely manner.
INTRODUCTION: The US Food and Drug Administration uses drug safety communications (DSCs) to release emerging information regarding post-market safety issues, but it is unclear the extent of awareness by patients and providers of these communications and their specific recommendations. OBJECTIVE: We conducted semi-structured interviews with patients and physicians to evaluate their awareness and understanding of emerging drug safety information related to two sleep aids: zolpidem or eszopiclone. METHODS: We conducted interviews with 40 patients and ten physicians recruited from a combination of insurer claims databases and online sources. We evaluated (1) sources of drug safety information; (2) discussions between patients and physicians about the two medications; (3) their knowledge of the DSC; and (4) preferences for learning about future drug safety information. Interviews were transcribed and analyzed thematically. RESULTS:Patients cited their physicians, pharmacy inserts, and the Internet as sources of drug safety information. Physicians often referred to medical journals and online medical sources. Most patients reported being aware of information contained in the DSC summaries they were read. Almost all patients and physicians reported discussing side effects during patient-provider conversations, but almost no patients mentioned that physicians had communicated with them key messaging from the DSCs at issue: the risk of next-morning impairment with zolpidem and the lower recommended initial dose for women. CONCLUSIONS: Some risks of medications are effectively communicated to patients and physicians; however, there is still a noticeable gap between information issued by the Food and Drug Administration and patient and physician awareness of this knowledge, as well as patients' decisions to act on this information. Disseminators of emerging drug safety information should explore ways of providing user-friendly resources to patients and healthcare professionals that can update them on new risks in a timely manner.
Authors: Stacie B Dusetzina; Ashley S Higashi; E Ray Dorsey; Rena Conti; Haiden A Huskamp; Shu Zhu; Craig F Garfield; G Caleb Alexander Journal: Med Care Date: 2012-06 Impact factor: 2.983
Authors: Aaron S Kesselheim; Eric G Campbell; Sebastian Schneeweiss; Paula Rausch; Brian M Lappin; Esther H Zhou; John D Seeger; John S Brownstein; Steven Woloshin; Lisa M Schwartz; Timothy Toomey; Gerald J Dal Pan; Jerry Avorn Journal: Drug Saf Date: 2015-06 Impact factor: 5.606
Authors: Caitlin Knox; Christian Hampp; Mary Willy; Almut G Winterstein; Gerald Dal Pan Journal: Pharmacoepidemiol Drug Saf Date: 2015-03-23 Impact factor: 2.890
Authors: Michael Conrardy; Patrick Lank; Kenzie A Cameron; Ryan McConnell; Alison Chevrier; Jill Sears; Eric Ahlstrom; Michael S Wolf; D Mark Courtney; Danielle M McCarthy Journal: Pain Med Date: 2016-01 Impact factor: 3.750
Authors: Laura P Richardson; Charlotte W Lewis; Mary Casey-Goldstein; Elizabeth McCauley; Wayne Katon Journal: J Adolesc Health Date: 2007-02-15 Impact factor: 5.012
Authors: Aaron S Kesselheim; Michael S Sinha; Eric G Campbell; Sebastian Schneeweiss; Paula Rausch; Brian M Lappin; Esther H Zhou; Jerry Avorn; Gerald J Dal Pan Journal: Drug Saf Date: 2019-11 Impact factor: 5.606
Authors: Helen W Sullivan; Claudia Squire; Kathryn J Aikin; Janice Tzeng; Kate Ferriola-Bruckenstein; Eric Brodsky; Ann Marie Trentacosti; Mihaela Johnson Journal: Res Social Adm Pharm Date: 2021-08-01
Authors: Bo-Ram Yang; Kyu-Nam Heo; Yun Mi Yu; Ga-Bin Yeom; Hye Duck Choi; Ju-Yeun Lee; Young-Mi Ah Journal: Int J Environ Res Public Health Date: 2021-05-12 Impact factor: 3.390
Authors: William Galanter; Tewodros Eguale; Walid Gellad; Bruce Lambert; Maria Mirica; John Cashy; Alejandra Salazar; Lynn A Volk; Suzanne Falck; John Shilka; Elizabeth Van Dril; Jennie Jarrett; John Zulueta; Julie Fiskio; John Orav; Diana Norwich; Samuel Bennett; Diane Seger; Adam Wright; Jeffrey A Linder; Gordon Schiff Journal: JAMA Netw Open Date: 2021-07-01